Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

NCT04729387 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

358

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Ovarian Cancer

Interventions

DRUG: Alpelisib
DRUG: Olaparib
DRUG: Paclitaxel
DRUG: Pegylated liposomal doxorubicin (PLD)

Sponsor

Novartis Pharmaceuticals